Document:

Exhibit 10.46

 

[Portions of this exhibit have been omitted
because the information is both not material and would likely cause competitive harm to the registrant if publicly disclosed. The
omissions have been indicated by bracketed asterisks (“[***]”).]

 

JOINT DEVELOPMENT AGREEMENT

 

This Agreement (“Agreement”)
is by and between LINEARX, Inc., a Delaware corporation, having a place
of business at 50 Health Sciences Drive, Stony Brook, New York 11790 (hereinafter “LINEARX”),
TAKIS S.R.L. (“TAKIS”) and EVVIVAX S.R.L., (“EVVIVAX) both
Italian limited liability companies, having a place of business at Via di Castel Romano 100, 00128 Roma, Italy, referred
to individually as a “Party” and collectively as “the Parties.”

 

Recitals

 

WHEREAS, LINEARX is engaged in research,
development and manufacture of PCR produced linear DNA technologies for use in DNA based therapeutics;

 

WHEREAS, TAKIS is engaged in the
research and development of a DNA based targeted cancer vaccines and associated electroporation device for human therapeutic markets;

 

WHEREAS, EVVIVAX is a wholly owned
subsidiary of TAKIS, and is engaged in the research and development of a DNA based targeted vaccines against Cancer and Infectious
Diseases for veterinary therapeutic markets;

 

WHEREAS, the Parties wish to participate
in a joint development of DNA based targeted cancer vaccine comprised of PCR produced linear DNA, derived from, or incorporating
LINEARX’s PCR produced linear DNA technologies and TAKIS’ and EVVIVAX’ DNA based targeted cancer vaccines;

 

WHEREAS, the Parties are willing
to grant to each other rights to their background intellectual property during the joint development program to permit them to
conduct their research and development activities under this Agreement in accordance with the terms and conditions set forth herein;
and

 

WHEREAS, the Parties desire to allocate
ownership and license rights to the technology developed by, or acquired by either of them for, the joint development program on
the terms set forth herein.

 

NOW, THEREFORE, in consideration
of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

Article 1

Definitions

 

1.1 “LINEARX Background Intellectual
Property” shall mean the Background Intellectual Property owned by LINEARX and as set forth in Exhibit B.

 

    1

     

    

 

1.2 "LINEARX Field" means
PCR (or other enzymatic process) produced nucleic acid constructs/vectors for use in nucleic
acid based therapeutics.

 

1.3 “Affiliate” means,
with respect to a Party, any corporation, firm, partnership, individual or other form of business organization which controls or
is controlled by such Party, but only so long as such control exists. An entity or individual shall be regarded as in control of
another corporation or other entity if it owns or directly or indirectly controls at least fifty percent (50%) of the voting stock
of the other corporation, or in the absence of ownership of at least fifty percent (50%) of the voting stock of a corporation,
if it possesses, directly or indirectly, the power to direct or cause the direction of the management of the corporation.

 

1.4 “Background Intellectual Property”
means Intellectual Property controlled by a Party which is useful to permit the other Party to perform its obligations under this
Agreement and: (a) was made, invented, developed, created, conceived, reduced to practice, or has a filing date before the
Effective Date and is not Generated Intellectual Property; or (b) was acquired by a Party during the Term of this Agreement,
other than by joint acquisition or ownership with the other Party and is not Generated Intellectual Property. Background Intellectual
Property includes, with respect to each of the foregoing items, all rights in any patents or patent applications, copyrights, trade
secret rights, and other Intellectual Property rights relating thereto. Background Intellectual Property includes each respective
Party’s Background Intellectual Property listed in Exhibit B as it may be amended by the Parties from time to time.

 

1.5 “Confidential Information”
means any business or technical information that is disclosed hereunder by one Party or any of its Affiliates (the disclosing Party)
to the other Party or any of its Affiliates (the receiving Party). Confidential Information shall include any and all technical
and business information, whether written, oral or graphic, that representatives of either Party may disclose or reveal to the
other Party, including but not limited to financial plans and records, Information, marketing plans, business strategies and
relationships with third parties, client lists, present and proposed products, trade secrets, information regarding customers and
suppliers, founders, employees and affiliates, that the receiving Party has a reasonable basis to believe is confidential to the
disclosing Party and is treated by the disclosing Party as confidential. Confidential Information shall also include the terms
of this Agreement. Samples provided by one Party to the other are understood to be Confidential Information of the providing Party.
Such Confidential Information shall not include information that:

 

	 	a)	was known to the receiving Party prior to receipt from the disclosing Party, as documented in written records or publications that lawfully are in the possession of the receiving Party or known to the receiving Party prior to such receipt;

 

	 	b)	was lawfully available to the trade or to the public prior to receipt from the disclosing Party;

 

	 	c)	becomes lawfully available to the trade or to the public after receipt from the disclosing Party through no act or omission on the part of the receiving Party, its Affiliates or their directors, officers or employees;

 

    2

     

    

 

	 	d)	corresponds in substance to any information received in good faith by the receiving Party from any third party and which is not subject to confidentiality limitations; or

 

	 	e)	is independently developed by an employee or agent of the receiving Party, without reference to information received from the disclosing Party subsequent to receipt of such information from the disclosing Party.

 

For all purposes of this Agreement, Confidential
Information that is specific shall not be deemed to be within any of the specified exceptions merely because it is embraced by
more general information in such exception. In addition, any combination of features shall not be deemed to be within any of the
specified exceptions merely because individual features are in such exception, but only if the combination itself and its principle
of operation are in such exception.

 

1.6 “Effective Date”
means September 12, 2018.

 

1.7 “Generated Intellectual Property”
means all Intellectual Property made, invented, developed, created, conceived, or reduced to practice after the Effective Date
and as a result of the Joint Development Program.

 

1.8 "Intellectual Property"
means all patentable and unpatentable inventions, works of authorship or expression, including computer programs, data collections
and databases, trade secrets and Information.

 

1.9 “Information" means
any and all ideas, concepts, data, know-how, discoveries, improvements, methods, techniques, technologies, systems, specifications,
analyses, products, practices, processes, procedures, protocols, research, tests, trials, assays, controls, prototypes, formulas,
descriptions, formulations, submissions, communications, skills, experience, knowledge, plans, objectives, algorithms, reports,
results, conclusions, and other information and materials, irrespective of whether or not copyrightable or patentable and in any
form or medium (tangible, intangible, oral, written, electronic, observational, or other) in which such Information may be communicated
or subsist.

 

1.10 “Joint Development Program”
means all activities performed by the Parties or their respective Affiliates under this Agreement and which are authorized by this
Agreement.

 

1.11 “Joint Intellectual Property”
means all Generated Intellectual Property that is jointly conceived by one or more employees, agents, partners or non-Party independent
contractors of TAKIS and/or EVVIVAX and one or more employees, agents, partners or non-Party independent contractors of LINEARX.
Joint Intellectual Property, however, shall not include any intellectual property for subject matter developed independently by
any Party (whether before or after the Effective Date of this Agreement) and merely tested by the other pursuant to the Joint Development
Program.

 

1.12 "Losses" means all
losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs,
or expenses of whatever kind, including reasonable attorneys' fees and the cost of enforcing any right to indemnification hereunder
and the cost of pursuing any insurance providers.

 

    3

     

    

 

1.13 “Project Plan”
means the project plan(s) appended to this Agreement in Exhibit A and incorporated by reference.

 

1.14 “Raw Data” mean
the primary quantitative and empirical data collected by a Party from projects, experiments or clinical trials conducted under
the scope of this Agreement.

 

1.15 “Sole LINEARX Intellectual
Property” means all Generated Intellectual Property that is solely conceived by employees, agents, partners or non-party
independent contractors of LINEARX.

 

1.16 “Sole TAKIS Intellectual
Property” means all Generated Intellectual Property that is solely conceived by employees, agents, partners or non-party
independent contractors of TAKIS.

 

1.17 “Sole EVVIVAX Intellectual
Property” means all Generated Intellectual Property that is solely conceived by employees, agents, partners or non-party
independent contractors of EVVIVAX.

 

1.18 “TAKIS Background Intellectual
Property” shall mean the Background Intellectual Property owned by TAKIS.

 

1.19 “EVVIVAX Background Intellectual
Property” shall mean the Background Intellectual Property owned by EVVIVAX.

 

1.20 “TAKIS and EVVIVAX Field”
means DNA based targeted cancer vaccines and electroporation systems and methodologies relating thereto.

 

1.21 “Term” shall have
the meaning prescribed in Article 9.1 and shall include any Extension Terms as defined in Article 9.1.

 

Article 2

Joint
Development Program

 

2.1 From time to time hereunder, the Parties
may collaborate under the Joint Development Program on one or more projects. For each such project, the Parties will prepare a
written Project Plan describing the particular project, the duties of each Party under the project, the anticipated deliverables
and schedule for completion of such duties and deliverables. Unless expressly agreed otherwise in writing, all research and development
materials provided by one Party to the other will be provided without charge. Each Project Plan must be signed by both Parties
to be effective and shall thereafter be attached and integrated into this Agreement as a part of Exhibit A.

 

2.2 Each Party shall bear all of its own
fees, expenses, and/or costs of any kind hereunder, including without limitation, all costs incurred by a Party in association
with the activities outlined in Exhibit A.

 

2.3 Each Party shall designate at least
one project manager for each project as well as at least one program manager to help oversee the entire Joint Development Program.

 

    4

     

    

 

2.4 During the Term, each Party shall provide
to the other Party reasonable access to its facilities, books, and records, and such other Information that the providing Party
believes to be necessary or useful (i) to support the other Party's efforts to conduct its Joint Development Program activities
or (ii) for the other party to exercise its rights or meet its obligations under this Agreement, and any other Information
that the other party reasonably requests in support of the Joint Development Program. Notwithstanding the foregoing, neither Party
is required to provide any books, records or Information that is/are not required or useful for the other Party to perform its
obligations or exercise its rights under this Agreement.

 

2.5 Each Party shall disclose to the other
Party all Generated Intellectual Property, including copies of all invention disclosures and other similar documents created in
the normal course of its business that disclose any conception or reduction to practice of any Intellectual Property constituting
Generated Intellectual Property. A party shall make all such disclosures to the other party at least thirty (30) days before any
public disclosure of such Intellectual Property.

 

Article 3

Ownership
of Intellectual Property

 

3.1 Subject to the licenses granted herein,
LINEARX shall own all LINEARX Background Intellectual Property and Sole LINEARX Intellectual Property.

 

3.2 Subject to the licenses grated herein,
TAKIS shall own all TAKIS Background Intellectual Property and Sole TAKIS Intellectual Property.

 

3.3 Subject to the licenses grated herein,
EVVIVAX shall own all EVVIVAX Background Intellectual Property and Sole EVVIVAX Intellectual Property.

 

3.3 Subject to the licenses grated herein,
LINEARX and TAKIS or LINEARX and EVVIVAX shall jointly own all Joint Intellectual Property.

 

3.4 For the avoidance of doubt, the parties
agree that the results of the efforts by any Party under this Agreement shall not be considered “work for hire”, and
that no Party acquires any rights to, or licenses to use, any such results except as expressly set forth in this Agreement.

 

Article 4

Intellectual
Property Licensing

 

4.1 Background Intellectual Property

 

4.1.1 Subject to the terms and
conditions of this Agreement, LINEARX, on behalf of itself and its Affiliates, hereby grants to TAKIS and EVVIVAX during the Term
a fully paid up, non-exclusive, royalty-free, non-transferable, non-sublicensable license under the LINEARX Background Intellectual
Property to perform its obligations as reasonable necessary under the Joint Development Program.

 

4.1.2 Subject to the terms and
conditions of this Agreement, TAKIS and EVVIVAX, on behalf of themselves and their Affiliates, hereby grants to LINEARX during
the Term a fully paid up, non-exclusive, royalty-free, non-transferable, non-sublicensable license under the TAKIS Background Intellectual
Property to perform its obligations as reasonable necessary under the Joint Development Program.

 

    5

     

    

 

4.1.3 Notwithstanding any other
provision in this Agreement, under no circumstances shall a Party to this Agreement, as a result of this Agreement, have any right
under or to the Background Intellectual Property of the other Party except for the limited activities and purposes permitted by
the licenses granted by Article 4.1.1 and 4.1.2.

 

4.2 Generated Intellectual Property

 

4.2.1 LINEARX agrees to grant and does
hereby grant to TAKIS and EVVIVAX the exclusive, worldwide, royalty-bearing right under Joint Intellectual Property and Sole LINEARX
Intellectual Property to make, have made, make for others, use, sell, offer for sale, import, or otherwise commercially transfer
products in the TAKIS and EVVIVAX Field. The Parties agree that if TAKIS and /or EVVIVAX abandon all development and/or commercial
activities in the TAKIS and EVVIVAX Field for a period of more than one (1) year, the exclusive license granted to TAKIS and
EVVIVAX in this Section 4.2.1 shall revert to LINEARX.

 

4.2.2 TAKIS and EVVIVAX agree to grant
and do hereby grant to LINEARX the exclusive, worldwide, royalty-bearing right under Joint Intellectual Property and Sole TAKIS
and Sole EVVIVAX Intellectual Property to make, have made, make for others, use, sell, offer for sale, import, or otherwise commercially
transfer products in the LINEARX Field.

 

4.2.3 The Parties agree that the royalty
bearing nature of the licenses granted in Articles 4.2.1 and 4.2.2 are a conditions precedent to effectiveness of the commercial
licenses granted under Articles 4.2.1 and 4.2.2. The Parties shall negotiate the structure and financial terms (e.g. up-front payments,
royalties, license maintenance fees, milestone payments and/or other consideration) of the licenses granted in Articles 4.2.1 and
4.2.2 through arm’s length good faith negotiations. Any disagreement during the negotiation of the royalty bearing nature
of licenses granted by Articles 4.2.1 and 4.2.2 will, if possible, be resolved by the good faith attempts of the Parties under
Article 12.

 

4.2.4 Except as provided in Articles 4.2.1
and 4.2.2 above, each Party shall have the right to operate under Joint Intellectual Property and grant nonexclusive licenses to
third parties as they may desire without accounting to the other Party.

 

Article 5

Patent
Filing and Prosecution

 

5.1 LINEARX shall have the sole discretion
to file, prosecute, issue, and maintain patent applications and patents, throughout the world, claiming LINEARX Background Intellectual
Property or Sole LINEARX Intellectual Property. TAKIS and EVVIVAX shall have the sole discretion to file, prosecute, issue, and
maintain patent applications and patents, throughout the world, claiming TAKIS and EVVIVAX Background Intellectual Property or
Sole TAKIS and EVVIVAX Intellectual Property.

 

    6

     

    

 

5.2 LINEARX and TAKIS and/or EVVIVAX may
jointly file any applications for patents on inventions that are Joint Intellectual Property. The applications shall be prepared
and prosecuted by a mutually acceptable patent attorney with the expenses of preparation, prosecution and maintenance to be shared
equally between the Parties. If one Party elects not to pursue a patent application on an invention which is Joint Intellectual
Property, that Party shall assign its rights to the patent or patent application, as the case may be, to the other Party who wishes
to pursue such patent or patent application at its sole expense. LINEARX and TAKIS and/or EVVIVAX shall cooperate in prosecuting
any applications for patent(s) on inventions that are Joint Intellectual Property. Such cooperation will continue even if
a Party elects not to pursue an application for patent in Joint Intellectual Property and assigns its rights to the invention to
the other Party who pursues such application at its sole expense.

 

5.3 At least thirty (30) days prior to
a Party filing any patent application claiming Generated Intellectual Property, the Party desiring to file such an application
shall provide the other Party with a copy of the proposed application. The Party receiving the copy of the proposed application
shall then have thirty (30) days to notify the Party desiring to file as to whether it believes that any of its Confidential Information
is disclosed or if the invention is its own sole intellectual property or Joint Intellectual Property. If the application contains
any of the other Party’s Confidential Information, then the Party desiring to file the patent application shall either:

 

(a)  delete
such Confidential Information from the application prior to filing, or

 

(b)  where
disclosure of such Confidential Information in the patent application is necessary to comply with the statuary requirements of
any country in which the application will be filed, not file such application without the prior written permission of the Party
owning such Confidential Information.

 

5.4 In the event a Party is unable to provide
a copy of a proposed patent application at least thirty (30) days prior to filing the application pursuant to Article 5.3
due to reasonable business circumstances, the Party desiring to file such application shall file a provisional patent application
in order to preserve patent rights in the subject matter of such application and shall provide the other Party with a copy of the
provisional application within ten (10) days after filing the provisional application with the United States Patent Office
or other international filing office. The Party receiving the copy of the provisional patent application shall then have thirty
(30) days to notify the Party that filed the provisional application whether it believes that any of its Confidential Information
is disclosed or if the invention is its own sole intellectual property or Joint Intellectual Property. If the application contains
any of the other Party’s Confidential Information, then the Party who filed the provisional application shall either:

 

(a)  delete
such Confidential Information from the provisional application prior to filing any patent application claiming priority to the
provisional application, including a nonprovisional patent application or other patent application under the Patent Cooperation
Treaty or any foreign country laws, or

 

(b)  where
disclosure of such Confidential Information in the patent application is necessary to comply with the statuary requirements of
any country in which the application will be filed, not file any patent application that claims priority to the provisional application,
including a nonprovisional patent application or other patent application under the Patent Cooperation Treaty or any foreign country
laws, without the prior written permission of the Party owning such Confidential Information.

 

    7

     

    

 

5.5 If there is a dispute between the Parties
as to whether any Generated Intellectual Property is a sole or joint invention of the Parties, the dispute shall be resolved using
the inventorship laws of the United States. Disputes involving inventorship or whether a Party’s Confidential Information
is or should be disclosed in a patent application will, if possible, be resolved by the good faith attempts of the Parties under
Article 12.

 

ARTICLE 6

ENFORCEMENT OF GENERATED INTELLECTUAL
PROPERTY

 

6.1 A Party receiving notice of an alleged
infringement of any Joint Intellectual Property or is a party to a declaratory judgment action alleging the invalidity or non-infringement
of any Joint Intellectual Property, shall promptly, but no less than fifteen (15) days after receiving such notice, provide written
notice to the other Party of the alleged infringement or declaratory judgment action, as applicable. The Parties shall jointly
determine the Parties' response and course of action, including the commencement of any suit or other proceeding to enjoin, prohibit,
or otherwise secure the cessation of such infringement or other action. Subject to Article 6.2, if the Parties decide to proceed
with any such suit or other proceeding, the Parties shall:

 

	 	(a)	jointly select litigation counsel to prosecute the suit to maximize revenue from and create the best market environment for the Joint Intellectual Property;

 

	 	(b)	jointly select the forum for the suit and each join the suit as a party to perfect or maintain jurisdiction to continue the suit in such forum;

 

	 	(c)	cooperate with each other, including giving testimony and producing documents lawfully requested in the course of the suit or other proceeding and cause its representatives to cooperate with the other party;

 

	 	(d)	share equally all out-of-pocket costs and expenses, including reasonable attorneys' and experts' fees, incurred in commencing and maintaining such suit; and

 

	 	(e)	each have the right to receive payment of fifty percent (50%) of the balance of any settlement amount, damages, or other monetary awards recovered in connection with the suit or proceeding that remains after reimbursement of their respective actual out-of-pocket costs and expenses paid pursuant to Article, provided that, if the settlement or damage award amount does not fully reimburse the parties' aggregate out-of-pocket litigation costs and expenses, the settlement or damage award amount shall be shared equally by the Parties.

 

6.2 If one of the Parties elects not to proceed with a suit
or other proceeding as recommended by the other Party, the other Party may, but is not obligated to, commence and maintain such
suit or other proceeding at its own cost and expense. If that Party elects to proceed with the suit or other proceeding, the Party
electing to proceed shall have the exclusive right to:

 

    8

     

    

 

	 	(a)	select and retain litigation counsel of its choosing, with the advice and consent of the party that has elected not to so proceed, which consent shall not be unreasonably withheld or delayed; and

 

	 	(b)	direct and control such suit or other proceeding and receive and retain all settlement amounts, damages, and other monetary awards recovered in connection with it.

 

6.3 If the other Party is required under
applicable law to join any such suit or other proceeding to enforce any ownership or other rights in, or defend the validity of,
any Joint Intellectual Property, or if the failure of such other party to be a party to such suit or proceeding would, in the opinion
of counsel of the prosecuting or defending party, risk dismissal thereof, the other Party shall execute all papers and perform
such other acts as may be reasonably required to permit the suit or other proceeding to be brought and conducted (including initiating
a suit or proceeding before a court or tribunal at the prosecuting or defending party's request or permitting the prosecuting or
defending party to initiate or maintain such suit or proceeding in the name of itself and the other party). If the other Party
is required to be joined as a party as described in this Article 6.3, upon the request of the prosecuting or defending party,
the other Party shall and hereby does unconditionally and irrevocably waive any objection to such joinder on any grounds, including
on grounds of personal jurisdiction, venue, or forum non conveniens. The Party joined to such suit or proceeding may, at
its election and on written notice to the other Party, be represented by counsel for the prosecuting or defending party at such
prosecuting or defending party's cost and expense or be represented by counsel of its choice at its own cost and expense.

 

6.4 A Party initiating or defending any
suit or proceeding pursuant to Article 6.2 shall have the exclusive right, in its sole discretion, to settle and compromise
such suit or proceeding, whether by settlement or other voluntary final disposition, without the prior written approval of the
other party, provided that the terms of such resolution do not:

 

	 	(a)	enjoin any future action by the other Party or any of its Affiliates, licensees, sublicensees, or customers (including the other Party, “Affected Persons”)

 

	 	(b)	derogate from or diminish any of the other party's rights or licenses under this Agreement;

 

	 	(c)	require any of the Affected Persons to make any payment;

 

	 	(d)	fail to grant the other Party a release of all claims in the suit or proceeding;

 

	 	(e)	require the admission or concession that any claim or aspect of any Joint Intellectual Property is invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or patent; or

 

	 	(f)	otherwise have a material adverse effect upon any of the Affected Persons, any of their assets, or any objectives or subject matter of this Agreement.

 

    9

     

    

 

Article 7

Warranties
and Representations

 

7.1 Each of LINEARX, TAKIS and EVVIVAX,
respectively, warrant that it has no agreements with any third party or commitments or obligations that materially conflict with
its obligations under this Agreement. During the Term of this Agreement, neither Party will enter into any agreement, commitment
or obligation that materially conflicts with its obligations under this Agreement.

 

7.2 Each of LINEARX, TAKIS and EVVIVAX,
respectively, warrant that it has or will obtain from its employees, agents and consultants who perform work in accordance with
the Joint Development Program a valid and sufficient written agreement vesting ownership of all their discoveries, improvements,
inventions and ideas in LINEARX or TAKIS or EVVIVAX, respectively.

 

7.3 The Parties will use reasonable efforts
to satisfy their respective duties and provide the deliverables for each effective project; provided, however, that neither Party
represents or warrants that it will be able successfully to complete its assigned duties or deliverables.

 

Article 8

Confidentiality

 

8.1 The Parties signed a Mutual Confidential
Disclosure Agreement dated June 28, 2018 (hereinafter “Mutual Confidential Disclosure Agreement”). The terms of
this Agreement shall govern any Confidential Information disclosed pursuant to this Agreement. With respect to any other information
exchanged between the Parties, the Mutual Confidential Disclosure Agreement, or any such other agreement the Parties may enter
into from time to time, governs confidential treatment of such information.

 

8.2 LINEARX, TAKIS and EVVIVAX each agree
to maintain the other Party’s Confidential Information in confidence and not disclose the other Party’s Confidential
Information to any of its employees whose work does not require such disclosure or to any third party without the prior written
approval of the other Party, except as is expressly contemplated by this Agreement (including all Exhibits) or any subsequent Agreement
relating to the Joint Development Program or with respect to disclosures which are inherent in any products developed as a result
of the Joint Development Program. LINEARX, TAKIS and EVVIVAX each agree not to use any of the other Party’s Confidential
Information except to perform the tasks assigned to it with respect to the Joint Development Program, except as expressly authorized
in a written consent from the owner of such Confidential Information. Any disclosure to a third party shall be made pursuant to
a written agreement between the third party and the owner of the Confidential Information, in which the third party acknowledges
obligations of confidentiality and use consistent with those in this Agreement and the Mutual Confidential Disclosure Agreement.
The foregoing obligations shall remain in force for five (5) years following termination or expiration of this Agreement.

 

    10

     

    

 

8.3 Any provision of this Agreement to
the contrary notwithstanding, LINEARX, TAKIS and EVVIVAX are entitled to disclose Confidential Information to the extent reasonably
necessary for the purposes of this Agreement, to their respective Affiliates, on condition that such entities agree in a written
agreement between the Affiliate and the owner of the Confidential Information to be bound by this Agreement with respect to nondisclosure
and non-use of such Confidential Information. LINEARX , TAKIS and EVVIVAX warrant the compliance of their employees and Affiliates
with the terms of this Agreement.

 

8.4 The Parties acknowledge that the relationship
created by this Agreement and the existence and terms of this Agreement are confidential and that written approval will be obtained
from the other Party if a Party wishes to make any disclosure relating to the existence of the relationship between the Parties
and the existence and terms of this Agreement.

 

8.5 Neither Party will, without the prior written consent of
the other Party:

 

(a) use in advertising, publicity, or otherwise
in connection with products developed in accordance with this Agreement, any trade name, logo, trademark, trade device, service
mark, or symbol owned by the other Party; or

 

(b) represent, either directly or indirectly,
that any product or service of the other Party is a product or service of the representing Party, or vice versa.

 

8.6 If a Party is disclosing any Confidential
Information because it is required to do so to comply with a statute, ordinance or regulation or compulsory legal process, including,
without limitation, its reporting requirements under the Securities Exchange Act of 1934, as amended, such Party intending to make
such disclosure shall give the other Party at least five business days’ prior notice in writing of the text of the intended
disclosure, unless such statute, ordinance, regulation or compulsory legal process would require earlier disclosure, in which event
the notice shall be provided as early as practicable. A Party that determines it is required to file this Agreement with the Securities
and Exchange Commission or any other governmental authority, shall request confidential treatment with respect to the terms of
this Agreement, shall consult in good faith with the other Parties regarding such confidential treatment and shall use commercially
reasonable efforts to have redacted from any publicly available version such provisions as the Parties may agree from any copies
filed pursuant to such statute, ordinance, regulation or compulsory legal process.

 

8.7 If disclosure of Confidential Information
is being made in response to a valid order of a court of competent jurisdiction or other competent authority, the disclosing Party
shall give the other Party a reasonable opportunity to quash any such order or obtain a protective or, if disclosed, be used only
for the purpose for which the order was issued; and provided further that if such order is not quashed or a protective order is
not obtained, such information disclosed in response to the order of a court or other competent authority shall be limited to that
information that is legally required to be disclosed in response to such order.

 

8.8 Upon termination of the Joint Development
Program, and except as is required to practice any licenses granted under this Agreement, both LINEARX and its Affiliates and TAKIS,
EVVIVAX and their Affiliates agree to return all Confidential Information (including tangible products or materials) received by
that Party from the other Party, at the request of the other Party; provided, however, that the receiving Party may retain one
(1) secure archival copy of any Confidential Information received in writing from another Party for record purposes to determine
its on-going confidentiality obligations under this Agreement.

 

    11

     

    

 

 

8.9 Each Party shall have the sole discretion
to decide whether and to what extent, if any, to share its Confidential Information with the other Party. Neither Party shall have
any express or implied obligation to share any of its Confidential Information or Background Intellectual Property with the other
Party unless expressly provided herein.

 

Article 9

Term
and Termination

 

9.1 The Joint Development Program shall
commence on the Effective Date and, unless earlier terminated in accordance with the terms of this Agreement, will continue until
two (2) years from the Effective Date (the “Term”). However, this Agreement may be extended for additional one
(1) year period(s) by written consent of both Parties (each an “Extension Term”). Notwithstanding the previous
sentence, the obligations and rights that accrued under Articles 3, 4, 6, 8, 9, 10, 11, 13, 14 and 15 shall survive the termination
or expiration of this Agreement.

 

9.2 This Agreement may be terminated by
any Party in the event of a material breach by the other Party of the terms of this Agreement, provided that the terminating Party
first gives the defaulting Party written notice of termination, specifying the grounds therefor, and the defaulting Party has had
thirty (30) days after such notice is given to cure the breach. If not so cured, this Agreement shall terminate at the expiration
of such thirty (30) days.

 

9.3 Any Party may terminate this Agreement
without cause upon ninety (90) days written notice to the other Party.

 

Article 10

Disclaimers

 

10.1 NEITHER LINEARX NOR TAKIS NOR EVVIVAX
SHALL UNDER ANY CIRCUMSTANCES BE LIABLE TO EACH OTHER OR THEIR RESPECTIVE AFFILIATES FOR INDIRECT, INCIDENTAL, SPECIAL OR
CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF PRODUCTION TIME, PROFITS, REVENUE, OR BUSINESS) RESULTING FROM OR
IN ANY WAY RELATED TO THIS AGREEMENT, OR THE TERMINATION OF THIS AGREEMENT, OR ARISING OUT OF OR ALLEGED TO HAVE ARISEN OUT OF
(I) BREACH OF THIS AGREEMENT, (II) THE FAILURE BY ANY PARTY TO DEVELOP ANY PRODUCTS OR PROCESSES IN ACCORDANCE WITH THE
JOINT DEVELOPMENT PROGRAM, (III) THE FAILURE BY ANY PARTY TO DEVOTE THE RESOURCES SPECIFIED IN A PROJECT PLAN, (IV) THE
FAILURE BY ANY PARTY TO COMPLY WITH THE EXPRESS CONDITIONS SPECIFIED IN THE JOINT DEVELOPMENT PROGRAM, OR (V) ANY EVENT RELATED
TO THE CONDUCT OF THE JOINT DEVELOPMENT PROGRAM. THIS LIMITATION APPLIES REGARDLESS OF WHETHER SUCH DAMAGES ARE SOUGHT BASED ON
BREACH OF CONTRACT, NEGLIGENCE, OR ANY OTHER LEGAL THEORY.

 

    12

     

    

 

10.2 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED
IN THIS AGREEMENT OR THE EXHIBITS TO THIS AGREEMENT, LINEARX EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES WITH RESPECT
TO ANY LINEARX BACKGROUND INTELLECTUAL PROPERTY, INFORMATION OR KNOW-HOW, AND HEREBY EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

 

10.3 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED
IN THIS AGREEMENT OR THE EXHIBITS TO THIS AGREEMENT, TAKIS EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO
ANY TAKIS BACKGROUND INTELLECTUAL PROPERTY, INFORMATION OR KNOW-HOW, AND HEREBY EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

 

10.4 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED
IN THIS AGREEMENT OR THE EXHIBITS TO THIS AGREEMENT, EVVIVAX EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES WITH RESPECT
TO ANY EVVIVAX BACKGROUND INTELLECTUAL PROPERTY, INFORMATION OR KNOW-HOW, AND HEREBY EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

 

10.5 EACH PARTY EXPRESSLY DISCLAIMS ANY
EXPRESS OR IMPLIED WARRANTY, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARISING OUT OF ITS
PERFORMANCE OR ATTEMPTED DEVELOPMENT PURSUANT TO THIS AGREEMENT.

 

10.5 Neither Party warrants nor represents
that any product, apparatus or process conceived, developed or used in accordance with the Joint Development Program does not infringe
any intellectual property rights of any third party. Each Party will, however, notify the other Party promptly if a Party has a
reasonable basis for believing that any such product or process would infringe any intellectual property right of a third party.

 

Article 11

Indemnification

 

11.1 Each Party shall indemnify, defend,
and hold harmless the other Party and its officers, directors, employees, agents, successors, and assigns against all Losses arising
out of or resulting from any third party claim, suit, action, or proceeding related to or arising out of or resulting from (a) the
other Party's breach of any representation, warranty, covenant, or obligation under this Agreement; or (b) use by a Party
of the other party's Background Intellectual Property in connection with any activities performed pursuant to the Joint Development
Program (each an "Action").

 

    13

     

    

 

11.2 The indemnitee shall promptly notify
indemnitor in writing of any Action and cooperate with the indemnitee at the indemnitor's sole cost and expense. The indemnitor
shall immediately take control of the defense and investigation of the Action and shall employ counsel reasonably acceptable to
the indemnitee to handle and defend the Action, at the indemnitor's sole cost and expense. The indemnitor shall not settle any
Action in a manner that adversely affects the indemnitee's rights without the indemnitee's prior written consent, which shall not
be unreasonably withheld or delayed. The indemnitee's failure to perform any obligations under this Article 11.2 shall not
relieve the indemnitor of its obligation under this Article 11.2 except to the extent that the indemnitor can demonstrate
that it has been materially prejudiced as a result of the failure. The indemnitee may participate in and observe the proceedings
at its own cost and expense with counsel of its own choosing.

 

Article 12

Dispute
Resolution

 

12.1 The Parties shall attempt in good
faith to resolve any dispute arising out of or relating to this Agreement promptly by negotiation between executives who have authority
to settle the controversy and who are at a higher level of management than persons with direct responsibilities for administration
of this Agreement. A Party may give the other Party written notice of any dispute not resolved in the normal course of business.
Within fifteen (15) days after delivery of the notice, the receiving Party shall submit to the other a written response. The notice
and the response shall include (i) a statement of such Party’s position and a summary of arguments supporting the position,
and (ii) the name and title of the executive who will represent the Party and any other person who will accompany the executive.
Within thirty (30) days after delivery of the disputing Party’s notice, the executives of both Parties shall meet at a mutually
acceptable time and place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute. All reasonable
requests for information made by one Party to the other will be honored.

 

12.2 If the matter has not been resolved
within sixty (60) days after the disputing Party’s initial notice, or if the Parties fail to meet within thirty (30) days
of such notice, a Party may initiate mediation of the controversy or claims as provided below in Article 12.3.

 

12.3 If the dispute has not been resolved
by negotiation as provided above, the Parties shall endeavor to settle the dispute by mediation under the then current Rules of
the American Arbitration Association. The neutral third party mediator will be selected by the Parties, unless the Parties agree
otherwise. The Parties shall each pay one half of any fees and expenses payable to the third party mediator. Mediation shall be
venued in New York City, New York and conducted in the English Language.

 

12.4 All negotiations pursuant to this
Article are confidential and shall be treated as compromise and settlement negotiations for purposes of the United States
Federal Rules of Evidence and state rules of evidence.

 

    14

     

    

 

12.5 If the Parties fail to resolve the dispute through mediation
within forty-five (45) days of the request for mediation, then a Party may pursue its remedies in the United States Federal District
Court for the District of the Southern District of New York.

 

12.6 Notwithstanding the provisions of this Article 12,
the Parties shall not be required to attempt to negotiate or mediate the dispute if it relates to a breach of the provisions of
Article 8 (Confidentiality).

 

ARTICLE 13

BANKRUPTCY

 

13.1 All rights and licenses granted by
one Party to the other Party under this Agreement are and shall be deemed to be rights and licenses to "intellectual property"
as such term is used in and interpreted under, Article 365(n) of the United States Bankruptcy Code (the "Bankruptcy
Code").

 

13.2 Each party shall have the right to
exercise all rights and elections under the Bankruptcy Code with respect to the Generated Intellectual Property, and Background
Intellectual Property. Without limiting the generality of the foregoing, each party acknowledges and agrees that, if it becomes
subject to any bankruptcy or similar proceeding subject to the other party's rights of election, all rights and licenses granted
to the other party under this Agreement shall continue subject to the terms and conditions of this Agreement, and shall not be
affected, even by the rejection of this Agreement.

 

13.3 If a bankruptcy or similar proceeding
is commenced during the Term by or against a Party then, unless and until this Agreement is rejected as provided in the Bankruptcy
Code, the bankrupt party (in any capacity, including debtor-in-possession) and its successors and assigns (including, without limitation,
a trustee) shall perform all of the obligations provided in this Agreement to be performed by that Party. If (a) a bankruptcy
case is commenced during the Term by or against a party, and (b) this Agreement is rejected as provided in the Bankruptcy
Code and (c) the other party elects to retain its rights hereunder as provided in the Bankruptcy Code, then the bankrupt party,
subject to the bankruptcy case (in any capacity, including debtor-in-possession) and its successors and assigns (including, without
limitation, a Title 11 trustee), shall provide to the other party within thirty (30) days of the filing of the petition for bankruptcy
protection copies of all Information necessary for that party to prosecute, maintain, and enjoy its ownership and license rights
under the bankrupt party's Background Intellectual Property and Generated Intellectual Property under the terms of this Agreement.
All rights, powers, and remedies of the non-bankrupt party provided herein are in addition to and not in substitution for any and
all other rights, powers, and remedies now or hereafter existing at law or in equity (including, without limitation, the Bankruptcy
Code) in the event of the commencement of a bankruptcy case.

 

Article 14

Publication

 

14.1 The Parties acknowledge that inadvertent
publication of the results arising under any project under this Agreement may jeopardize patent protection. Notwithstanding the
foregoing, the Parties acknowledge the importance of publications. The provisions of this Article 14 are intended to promote
and ensure timely publication of results of projects, inventions, Information and/or Raw Data while protecting patent rights
and Confidential Information.

 

    15

     

    

 

14.2 In the event a Party wants to publish
or present any or all of the results, inventions, Information and/or Raw Data, it shall submit to the other Party the manuscript,
abstract or other proposed publication at least thirty (30) days prior to submission and, in the case of poster boards or other
presentations, at least forty-five (45) days prior to the presentation itself (the “Initial Review Period”). The non-publishing
Party shall timely review the proposed publication. The non-publishing Party may, together with the publishing Party, revise the
manuscript or other proposed publication to ensure protection of the non-publishing Party’s Confidential Information. Upon
non-publishing Party’s request, the publishing Party shall delay submission or publication for up to an additional thirty
(30) days (the “Supplemental Review Period”) if non-publishing Party deems it reasonably necessary to enable the non-publishing
Party or the publishing Party (as the case may be) to apply for patent protection covering any results, inventions, Information
and/or Raw Data disclosed in the proposed publication. In exercising its rights under this Article, the non-publishing Party will
not unreasonably withhold or delay consent.

 

Article 15

Miscellaneous

 

15.1 This
Agreement may not be assigned by a Party without the prior written consent of the Other Party (such consent not to be unreasonably
withheld, conditioned or delayed); provided, however, that, a Party may assign this Agreement to its Affiliate or to a Third Party
without such prior written consent as part of a merger, consolidation, sale, or transfer of all or substantially all its assets
associated with that portion of its business related to the subject matter of this Agreement, but only if the assignee has or simultaneously
acquires all of the necessary rights and other assets to perform such Party’s obligations under this Agreement.

 

15.2 Nothing
herein contained shall constitute a partnership between or joint venture by the Parties hereto or constitute any Party the agent
of the other. No Party shall hold itself out contrary to the terms of this Article and no Party shall become liable by any
representation, act or omission of the other contrary to the provisions hereof. This Agreement is not for the benefit of any third
party and shall not be deemed to give any right or remedy to any such party whether referred to herein or not.

 

15.3
No provision of this Agreement shall be waived unless in writing and signed by all Parties to this Agreement. The waiver
of any provision of this Agreement shall not be deemed to be a continuing waiver or the waiver of any other provision of this Agreement.

 

15.4 If any one or more of the provisions
contained in this Agreement, or any application thereof is held to be invalid, illegal, or unenforceable in any respect for any
reason, then such invalidity, illegality, or unenforceability shall not affect any other provision hereof or any other application
of the affected provision. It is the intention of the Parties that if any provision or application thereof is held to be invalid,
illegal, or unenforceable, there shall be substituted in lieu thereof a valid and enforceable provision or application as similar
in terms to such provision or application as is possible.

 

    16

     

    

 

15.5 This Agreement will be construed and
enforced in accordance with the laws of the State of New York, United States of America, without regard to any choice or conflict
of laws, rule or principle that would result in the application of the laws of any other jurisdiction. The New York State
Supreme Court, County of New York, or the United States District Court for the Southern District of New York shall have exclusive
jurisdiction to adjudicate any dispute arising in connection with this Agreement and each party hereby consents to such jurisdiction.

 

15.6 Any captions, Article numbers,
and any table of contents appearing in this Agreement are inserted only as a matter of convenience and do not define, limit, explain,
or modify the scope or intent of such Articles nor in any way affect this Agreement.

 

15.7 This Agreement shall be binding upon,
and inure to the benefit of, and be enforceable by the Parties and their respective successors and assigns.

 

15.8 This Agreement and any Exhibits may
be modified only by written agreement of the authorized representatives of each party.

 

15.9 Neither party will be liable for any
failure to perform under this Agreement to the extent such failure is caused by any reason beyond the party’s control including
the following occurrences: labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval required
for full performance, civil disorders or commotions, acts of aggression, cyber incident, floods, earthquakes, acts of God, energy
or other conservation measures, explosion, failure to utilities, mechanical breakdowns, material shortages, disease or other such
occurrences.

 

15.10 This Agreement, including any Exhibits,
constitutes the entire understandings of the Parties with respect to the subject matter of this Agreement. All prior agreements,
whether oral or written, are superseded by this Agreement.

 

15.11 This
Agreement has been negotiated and prepared by the Parties and their respective counsel, and should any provision of this Agreement
require judicial interpretation, the court interpreting or construing the provision shall not apply the rule of construction
that a document is to be construed more strictly against one party.

 

15.12
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall
be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service (with signature required),
by facsimile, or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the addresses
set forth herein.

 

15.13
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of
which together shall constitute one and the same Agreement.

 

    17

     

    

 

IN WITNESS THEREOF,
the Parties, through their authorized officers, have executed this Agreement as of the Effective Date.

 

	LineaRX, Inc.  
	 
	 
	By: 	/s/ James A. Hayward  	 
	 
	Name: James Hayward  
	 
	Title: Chief Executive Officer
	 
	Date: September 11, 2018

 

	Takis S.R.L.  
	 
	 
	By:	/s/ Luigi Aurisicchio  	 
	 
	Name:Luigi Aurisicchio  
	 
	Title: Chief Executive Officer  
	 
	Date: September 11, 2018

 

	Evvivax S.R.L.  
	 
	 
	By:	/s/ Luigi Aurisicchio	 
	 
	Name: Luigi Aurisicchio  
	 
	Title: Chief Executive Officer  
	 
	Date: September 11, 2018  

 

    18

     

    

 

[Portions of this exhibit have been omitted
because the information is both not material and would likely cause competitive harm to the registrant if publicly disclosed. The
omissions have been indicated by bracketed asterisks (“[***]”).]

 

Exhibit A

(Project Plan)

 

PURPOSE: The scope of this series
of studies is to extend the evaluation of PCR products delivered by DNA Electroporation to induce antigen-specific immune responses
aiming at achieving therapeutic effects in preclinical models and evaluate potential toxicologic effects. The plan is subdivided
in four phases:

 

PHASE 1: Vaccine Design

 

[***]

 

PHASE 2: Rodent Studies

 

[***]

 

PHASE 3: Dog Studies

 

[***]

 

PHASE 4: Tox Studies

 

[***]

 

    19

     

    

 

[Portions of this exhibit have been omitted
because the information is both not material and would likely cause competitive harm to the registrant if publicly disclosed. The
omissions have been indicated by bracketed asterisks (“[***]”).]

 

Exhibit B

(Background IP)

 

LineaRX:

 

[***]

 

Takis:

 

[***]

 

Evvivax:

 

[***]

 

    20

     

    

 

 

[Portions of this exhibit have been omitted
because the information is both not material and would likely cause competitive harm to the registrant if publicly disclosed. The
omissions have been indicated by bracketed asterisks (“[***]”).]

 

FIRST AMENDMENT TO JOINT DEVELOPMENT
AGREEMENT

 

THIS FIRST AMENDMENT
TO JOINT DEVELOPMENT AGREEMENT (this "Amendment") is made as of February 3, 2020, by and among LINEARX, INC.,
a Delaware corporation ("LINEARX") and TAKIS S.R.L. ("TAKIS") and EVVIVAX S.R.L., ("EVVIVAX)
both Italian limited liability companies, having a place of business at Via di Castel Romano 100, 00128 Roma, Italy, referred
to individually as a "Party" and collectively as "the Parties." .

 

RECITALS

 

WHEREAS, the Parties
entered into a Joint Development Agreement (the "Agreement") effective September 11, 2018;

 

WHEREAS, the Parties
have been conducting joint development as contemplated by the Agreement and wish to address additional opportunities for joint
development as set forth in this Amendment;

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound hereby, agree as follows:

 

AGREEMENT

 

1.           Definitions.
Capitalized terms used herein without definition shall have the meanings given to such terms in the Agreement.

 

2.           Amendments.

 

a.          The
fourth WHEREAS clause under Recitals in the Agreement is hereby deleted in its entirety and replaced with the following:

 

WHEREAS, the Parties wish
to participate in a joint development of DNA-based vaccines comprised of PCR produced linear DNA amplicons, derived from. or incorporating
LINEARX's PCR produced linear DNA technologies and TAKIS' and EVVIVAX'S DNA based vaccine candidates for cancer and 2019-nCov;

 

b.          Section 1.20
of in the Agreement is hereby deleted in its entirety and replaced with the following:

 

1.20 "TAKIS and EVVIVAX
Field" means DNA based cancer vaccines and DNA based vaccines for 2019-nCov, as well as electroporation systems and methodologies
relating thereto.

 

c.          Exhibit A
(Project Plan) of the Agreement is hereby amended by adding the following separate additional study to the Project Plan:

 

[***]

 

    	 	-1-	 

    	 	 	 

    

 

[Portions of this exhibit have been omitted
because the information is both not material and would likely cause competitive harm to the registrant if publicly disclosed. The
omissions have been indicated by bracketed asterisks (“[***]”).]

 

(d)         Exhibit B
(Background IP) of the Agreement is hereby amended by adding the following to the LineaRx Background IP - Patent Applications:

 

[***]

 

(e)         Exhibit B
(Background IP) of the Agreement is hereby amended by adding the following to the LineaRx Background IP - Patents:

 

[***]

 

(d)         Exhibit B
(Background IP) of the Agreement is hereby amended to add the following section:

 

[***]

 

3.           Consent.
Each Party consents to this Amendment.

 

    	 	-2-	 

    	 	 	 

    

 

4.            Continuation
of Agreement. Except as modified by this Amendment, the Agreement shall remain unchanged and continue in full force and effect.

 

5.            Entire
Agreement. This Amendment contains the entire agreement among the parties with respect to the subject matter hereof and supersede
all prior arrangements and understandings with respect thereto.

 

6.            Binding
Effect. This Amendment shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their
respective legal representatives, successors and assigns.

 

7.            Governing
Law. This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of New York.

 

8.            Severability.
If one or more provisions of this Amendment are held to be unenforceable under applicable law, such provision shall be excluded
from this Amendment and the balance of this Amendment shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.

 

9.            Counterparts;
Facsimile or Electronic Transmission. This Amendment may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. A facsimile or electronic transmission of
a scanned copy of a signed counterpart signature page hereto shall be deemed to be an originally executed copy for purposes
of this Agreement.

 

[Signature page follows]

 

    	 	-3-	 

    	 	 	 

    

 

IN WITNESS WHEREOF, each of the parties
hereto has executed this Amendment as of the date first above written.

 

	LineaRX, Inc.	 
	 	 
	By:	/s/ James A. Hayward	 
	 	 	 
	Name:	James Hayward	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	February 5, 2020	 

 

	Takis S.R.L.	 
	 	 
	By:	/s/ Luigi Aurisicchio	 
	 	 	 
	Name:	Luigi Aurisicchio	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	February 5, 2020	 

 

	Evvivax S.R.L.	 
	 	 	 
	By:	/s/ Luigi Aurisicchio	 
	 	 	 
	Name:	Luigi Aurisicchio	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	February 5, 2020Exhibit 10.47

 

ANIMAL CLINICAL TRIAL AGREEMENT (SARS-CoV-2)

 

THIS ANIMAL CLINICAL TRIAL AGREEMENT
made and effective as September 14, 2020 (herein the “Effective Date”) by and between APPLIED DNA SCIENCES, INC.,
a Delaware Corporation, with an address of 50 Health Sciences Drive, Stony Brook, NY 11790 (herein “Applied DNA”),
EVVIVAX S.R.L., a Italian Limited Liability Company, with an address of Via di Castel Romano 100, 00128 Roma, Italy (herein
 “Evvivax” and together with Applied DNA herein the “Sponsors”), and VETERINARY ONCOLOGY
SERVICES, PLLC, a New York Limited Liability Company, with an address of 69 Dakota Drive, Hopewell Junction, NY 12533, USA
(herein the “Clinical Research Team”).

 

WHEREAS, multiple studies have shown
that felis catus (domesticated cats) are susceptible to infection by SARS-CoV-2, the virus that causes the disease COVID-19
in humans;

 

WHEREAS, the Sponsors have jointly
developed PCR manufactured DNA-based vaccine candidates against SARS-CoV-2 that have shown the production of T cell immunity and
antibodies against SARS-CoV-2 in pre-clinical studies;

 

WHEREAS, the research program contemplated
by this Agreement is of mutual interest and benefit to Clinical Research Team and to the Sponsors and will potentially further
the development of a DNA-based vaccine against SARS-CoV-2 in domesticated cats;

 

NOW, THEREFORE, the parties hereto
agree as follows:

 

		1.	STATEMENT OF WORK. Clinical Research Team agrees to use its reasonable efforts to perform
the research program (herein the “Research Program”) as set forth in Exhibit A. Clinical Research Team shall
not make changes to the Research Program without the prior written consent of Sponsors. Clinical Research Team shall ensure that
staff members who are participating in the Research Program have been properly informed about the requirements of the Research
Program and the rules and regulations under which the Research Program is to be conducted, and have the necessary qualifications,
experience, authorizations and supervision to perform their assigned duties.

 

		2.	PRINCIPAL INVESTIGATOR. Elisa Sanchez, BS, LVT. If, for any reason, that person is unable
to continue to serve as Principal Investigator, Sponsors and Clinical Research Team shall attempt to find a successor acceptable
to both parties. If such a successor is not available, this Agreement shall be terminated as provided in Article 6.

 

		3.	PERIOD OF PERFORMANCE. The research to be conducted hereunder shall be conducted during
the period beginning on Fall 2020 and ending on 6-7 months post initiation of trial. (herein the “Termination Date”)
and will be subject to renewal only by mutual, written agreement of all parties.

 

		4.	RESEARCH DEVICE OR PRODUCTS. Sponsors shall provide the study device and/or products and
other components as appropriate for completion of the Research Program (“Research Materials”) to the Clinical Research
Team, free of cost. All Research Materials shall remain the property of the Sponsors during the Research Program and receipt, use,
and disposition of the Research Materials shall be accounted for by the Clinical Research Team. Research Materials shall be used
in connection with the Research Program and shall not be analyzed, transferred to a third party or used for any other purpose.
Upon the completion of the Research Program or termination of this Agreement, unless otherwise required by law or so notified by
Sponsors in writing, all remaining Research Materials will be stored under appropriate conditions by the Clinical Research Team
and then returned to Sponsors at Sponsors’ expense.

 

     1

     

    

 

		5.	COSTS. Each party agree to each their own costs to complete Research Program. Each party
acknowledges that it has sufficient funds to complete the Research Program. The parties acknowledge that, in compliance with all
applicable laws, the Clinical Research Team may charge animal owners to participate in the Research Program.

 

		6.	EARLY TERMINATION. Any party may terminate this Agreement upon thirty (30) days’ written
notice to all other parties. In the case of termination by Sponsors, Sponsors agree to pay all Research Program costs incurred
by the Clinical Research Team prior to the date of the written notice of termination.

 

		7.	REPORTS AND CONFIDENTIAL INFORMATION

 

		A.	From time to time during the term of this Agreement, Clinical Research Team may provide Sponsors
with written summaries on the progress of the Research Program. Clinical Research Team may also provide a summary report at the
completion of the Research Program.

 

		B.	All information and data, including without limitation any information about a disclosing party’s
technologies, the existence or nature of this Agreement, the Research Program and/or other scientific, pre-clinical, clinical,
regulatory, manufacturing, marketing, financial, trade secret, know-how and commercial information, tangible research products
or data that is provided by one party to the other party in connection with this Agreement (the “Confidential Information”)
shall be maintained in confidence by the receiving party and shall not be disclosed to any third parties or used for any purpose
except as set forth herein without the prior written consent of the disclosing party, except to the extent that such Confidential
Information:

 

		1.	is known by the receiving party at the time of its receipt, and not through a prior disclosure
by the disclosing party, as documented by the receiving party’s written records;

 

		2.	is in the public domain by use and/or publication before its receipt from the disclosing party,
or thereafter enters the public domain through no fault of the receiving party;

 

     2

     

    

 

		3.	is subsequently disclosed to the receiving party by a third party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing party; or

 

		4.	is developed by the receiving party independently of any Confidential Information received from
the disclosing party, as documented by the receiving party’s written records.

 

		A.	Confidential Information must be marked, and if disclosed orally,
summarized in writing within thirty (30) days of disclosure. Notwithstanding anything to the contrary in this Agreement, if a disclosing
party fails to mark an item of information as confidential or fails to reduce any oral disclosures to writing, such information
shall still be treated as Confidential Information for purposes of this Agreement if it is information that is commonly regarded
as confidential and/or proprietary. Each party will be considered the receiving party with respect to Confidential Information
that consists of knowledge of the existence of this Agreement, the nature of the Research program, and the fact that the parties
hereto are conducting or intend to conduct the Research Program, such that disclosures or uses thereof for any purpose except as
set forth herein will require the prior written consent of the other party; provided however, each party may disclose Confidential
Information to its employees, contractors, consultants, advisors, directors or investors who require access in order to perform
the Research Program and who have contractually agreed, either as a condition to employment or in order to obtain or access the
Confidential Information, to be bound by terms and conditions of confidentiality and non-use at least as stringent as the terms
of this Agreement. 

 

		D.	If a party is required by judicial or administrative process
to disclose the other party’s Confidential Information, including, without limitation, to one or more patent authorities
in connection with application(s) for patent, such party shall promptly inform the other party of the anticipated disclosure in
order to provide the other party an opportunity to challenge or limit the disclosure obligations. Any such Confidential Information
that is disclosed by judicial or administrative process or to any patent authority shall remain otherwise subject to the confidentiality
and non-use provisions of this Section, and the party that anticipates so disclosing such Confidential Information shall take all
steps reasonably practical, including without limitation seeking an order of confidentiality, to ensure the continued confidential
treatment of such Confidential Information.

 

		E.	Except as may be required to comply with any mandatory disclosure
obligation imposed by law, no party shall make any public announcement, publication or disclosure of the substance of this Agreement
or the nature of the Research Program without the prior written consent of the other parties, which consent shall not be unreasonably
withheld or delayed. Where a party believes that a mandatory disclosure obligation imposed by law requires it to disclose any of
the foregoing, it will exert commercially reasonable efforts so to notify the other parties in writing as much in advance of such
disclosure as the circumstances reasonably allow.

 

     3

     

    

 

		8.	PUBLICATIONS. Clinical Research Team or Sponsors shall have the right to publish or present
the results of its research performed hereunder with the prior written consent of the Sponsors and Clinical Research Team. Before
publishing with the consent of the Sponsors or Clinical Research Team, Clinical Research Team or Sponsors agree to submit copies
of any manuscript proposed for publication to Sponsors or Clinical Research Team at least thirty (30) days in advance of the presentation
or publication date, and if Sponsors or Clinical Research Team does not ask to defer publication within thirty (30) days after
receipt of the manuscript so that patent applications may be filed or Confidential Information removed, Sponsors or Clinical Research
Team may proceed with publication. In the event Sponsors or Clinical Research Team ask to defer publication, Sponsor or Clinical
Research Team shall not publish or otherwise disclose to any third party any of the information contained in the manuscript until
such time as a patent application has been filed or the expiration of sixty (60) days after the date of submission of the manuscript
to Sponsors or Clinical Research Team, whichever occurs first. In the case the objection to publication by the Sponsors or Clinical
Research Team is due to inclusion of Confidential Information, Sponsors or Clinical Research Team shall not published the manuscripts
until the Sponsors or Clinical Research Team agree it is free of Confidential Information. Any publications or presentation must
include Clinical Research Team on any or all research documents/manuscripts/marketing pieces directly involving the clinical research
results subject to the approval of the Clinical Research Team.

 

		9.	INTELLECTUAL PROPERTY

 

		A.	The Institute hereby assigns to the Sponsors
all intellectual property, including, but not limited to, all patents, patent applications, copyrights, discoveries and inventions,
whether patentable or not, conceived or reduced to practice by the Institute, alone or jointly with others, during the term of
this Agreement, which intellectual property either: (i) is based upon any Confidential Information received from Sponsors, or (ii)
is based upon the Institute’s use of the Research Materials during the Research Program (“Intellectual Property”).
The Institute agrees to disclose promptly and fully to Sponsors all Intellectual Property and to assist, and cause its employees
and agents assist Sponsors in every reasonable way, at Sponsors’ expense, to protect the rights of Sponsors in the Intellectual
Property, including, without limitation, to obtain patents and copyrights thereon in any and all countries.

 

		B.	It is acknowledged that each party is
entering into this Agreement with background intellectual property, which in the case of the Sponsors includes, without limitation,
the Research Materials and their methods of use as set forth in the Research Plan (the “Background Technologies”).
Each party retains all rights, title and interest in and to its respective Background Technologies. Neither party grants or shall
be required to grant to the other party, by implication or otherwise, any right or license under its Background Technology, nor
will a party be required to disclose any of its Background Technology to any other party, except as may be required to accomplish
the Research Plan. For clarity, the parties agree that, to the extent a license may be required from a party to another party to
conduct the Research Plan, the transfer of material a such party to the other as called for herein will constitute the grant of
a limited, non-exclusive, royalty-free, non-transferable license under the Background Technology, solely for the purpose of performing
the activities under the Research Plan, with no right to sublicense.

 

     4

     

    

 

		C.	Sponsors shall own all Data and have the right to use all Data in accordance with the terms of
this Agreement. Clinical Research Team hereby assigns, and agrees to assign, to Sponsor all right, title and interest in and to
all Data and progress reports created specifically for Sponsors in the performance of the Research Program. Notwithstanding any
licenses or other rights granted to Sponsors herein, but in accordance with Section 8, Clinical Research Team shall retain the
right to use the Data and results for its publication, regulatory, legal, educational, marketing and internal research purposes.
Clinical Research Team shall promptly disclose to Sponsors any and all Data. “Data” shall mean all data and information
generated by Clinical Research Team or its personnel as a result of conducting the Research Program. Data does not include original
Research Program subject or patient medical records, research notebooks, source documents, or other routine internal documents
kept in the Clinical Research Team’s ordinary course of business operations, which shall remain the sole and exclusive property
of the Clinical Research Team.

 

		10.	USE OF NAMES. No party to this Agreement will use the name of another party in any publication,
advertising, or other form of publicity without the written permission of the other party.

 

		11.	ANIMAL STUDIES. It is acknowledged that the Research Program will use live vertebrate animal
in the performance of research hereunder. All such use of live vertebrate animals in the performance of the research hereunder
shall comply with all applicable laws, government regulations, and guidelines. The Clinical Research Team represents and warrants
to the Sponsors that is has experience in the use of live vertebrate animals to conduct research and that all Institute activities
under the Research Program will comply with all applicable laws, government regulations, and guidelines, including, without limitation,
obtaining informed consent from all animal owners in the form annexed hereto as Exhibit C. The Research Materials shall
not be used in conjunction with human subjects.

 

		12.	INDEMNIFICATION. 

 

		A.	Sponsors jointly agree to defend, indemnify, and hold harmless the Clinical Research Team, the
Principal Investigator and each of their trustees, officers, directors, governing bodies, subsidiaries, affiliates, investigators,
employees, agents, successors, heirs and assigns (collectively referred to as “Clinical Research Team’s Indemnitees”),
from and against any third party claims, loss, damage, cost and expense of claims (including reasonable attorney’s fees)
and suits (“Claims”) alleged to be caused by or arising from (1) the conduct of the Research Program, (2) Clinical
Research Team’s use of the Research Material in accordance with this Agreement, or (3) Sponsors’ or any third party’s
use of the Research Program results or Research Materials, regardless of the legal theory asserted.

 

     5

     

    

 

		B.	Sponsors shall have no obligation to provide
such indemnification to the extent that such Claim is caused by or directly results from an Clinical Research Team’s Indemnitee(s)’:
(1) failure to adhere to and comply with all material and substantive specifications and directions set forth in this Agreement
or the Research Program or associated protocols (except to the extent such deviation is reasonable to protect the rights, safety
and welfare of the Research Program subjects); (2) failure to comply with all applicable laws and regulations in the performance
of the Research Program, (3) willful misconduct, negligent acts or omissions, or (4) breach of this Agreement.

 

		C.	Clinical Research Team shall indemnify,
hold harmless and defend Sponsors, their directors, officers, employees, subsidiaries and agents, (“Sponsor’s Indemnitees”)
from and against third party Claims to the extent directly caused by or resulting from an Clinical Research Team Indemnitee’s
willful misconduct or negligence in connection with the conduct of the Research Project. 

 

		D.	The indemnified Party shall give notice
to the indemnifying Party promptly upon receipt of written notice of a Claim for which indemnification may be sought under this
Agreement, provided, however, that failure to provide such notice shall not relieve indemnifying Party of its indemnification obligations
except to the extent that the indemnifying Party’s ability to defend such Claim is materially, adversely affected by such
failure. The indemnifying Party shall not make any settlement admitting fault or incur any liability on the part of the indemnified
Party without indemnified Party’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed.
The indemnified Party shall cooperate with indemnifying Party in all reasonable respects regarding the defense of any such Claim,
at indemnifying Party’s expense. The indemnified Party shall be entitled to retain counsel of its choice at its own expense.
In the event a Claim falls under this indemnification clause, in no event shall the indemnified Party compromise, settle or otherwise
admit any liability with respect to any Claim without the prior written consent of the indemnifying Party, and such consent not
to be unreasonably withheld or delayed.

 

		13.	SERIOUS ADVERSE EVENT REPORTING AND SUBJECT INJURY

 

		A.	Clinical Research Team shall report any serious adverse events (“SAE”) associated with
the Research Materials provided under this Agreement within 72 hours after identification of the SAE. Clinical Research Team shall
report any unanticipated adverse device effects (“UADE”) within ten (10) working days after the identification of the
UADE. Sponsors may terminate this Agreement immediately in the event Clinical Research Team fails to comply with its reporting
obligations.

 

     6

     

    

 

		B.	If a Research Program subject suffers an adverse reaction, illness, or injury which, in the reasonable
judgment of the Clinical Research Team, was directly caused by a Research Materials administered in accordance with this Agreement
and the Research Program, Sponsors shall provide reimbursement up to $5,000 per Research Program subject for reasonable and necessary
medical costs of diagnosis and medical treatment of any Research Program subject injury, including hospitalization, but only to
the extent such expenses are reasonable and necessary and not attributable to: (i) the Clinical Research Team’s negligence
or willful misconduct; or (ii) the Clinical Research Team’s breach of this Agreement.

 

		14.	CONFLICT OF INTEREST. Clinical Research Team and Primary Investigator represent that they
have advised Sponsors in writing prior to execution of this Agreement of any known relationship between Clinical Research Team
or Primary Investigator and a third party, including, without limitation, competitors of Sponsors, that would: (a) in any way present
a conflict of interest with the services to be performed under this Agreement; (b) present a significant opportunity for the disclosure
of Sponsors’ Confidential Information; or (c) in any way prevent any party from carrying out the terms of this Agreement.
Except with respect to known relationships identified above, Clinical Research Team represents that the terms of this Agreement
are valid and binding obligations of Clinical Research Team, and are not inconsistent with any other contractual and/or legal obligations
it may have, or with Clinical Research Team’s policies or the policies of any company with which it is associated.

 

		15.	DEBARMENT. Each party represents that neither it, nor any of its employees or agents performing
hereunder, have ever been, are currently, or are the subject of a proceeding that could lead to it or such employees or agents
becoming debarred or disqualified under applicable laws and regulations relating to clinical trials. Each party further represents
that if, during the term of this Agreement, it, or any of its employees or agents performing hereunder, become or are the subject
of a proceeding that could lead to that party, employee or agent becoming debarred or disqualified under applicable laws and regulations
relating to clinical trials, each party shall promptly, and in no event later than two (2) days after its first knowledge of such
proceeding or debarment, notify the other party, and the other party shall have the right to immediately terminate this Agreement.

 

		16.	NO REFERRALS. The parties acknowledge and agree that: (a) any compensation set forth in
Exhibit B is provided solely for the purposes of the study and represents the fair market value of the services provided,
negotiated in an arms-length transaction and has not been determined in a manner which takes into account the volume or value of
any referrals or business otherwise generated between Clinical Research Team and Sponsors; and (b) no provision of this Agreement
is intended as an inducement or offer to give or receive anything of value, either directly or indirectly, for the referral of
animal patients or for the arranging or furnishing of any item or service for which payment may be made by a government health
care program. In the event that Clinical Research Team or the Principal Investigator recommends Sponsors’ products to any
person or entity during the term of this Agreement, Clinical Research Team or the Principal Investigator, as applicable, shall
disclose this relationship with Sponsors in an effective manner.

 

     7

     

    

 

		17.	RELATIONSHIP OF THE PARTIES. Clinical Research Team relationship to Sponsors under this
Agreement is that of an independent contractor, and neither party has authority to bind or act on behalf of the other party. Clinical
Research Team represents that Principal Investigator’s relationship to Clinical Research Team is that of an independent contractor
acting under the guidance of the Clinical Research Team, and Sponsor further agrees to be responsible for compensating Principal
Investigator for his/her services. Further, the parties acknowledge that they are not “business associates” as that
term is defined under applicable law, and no party shall undertake any activity in this Agreement that could be construed as establishing
such a “business associate” relationship. The Clinical Research Team acknowledges that it is not an agent of Sponsors,
and has no authority to speak for, represent or obligate Sponsors in any way without first receiving written authority to do so
from Sponsors. The Sponsors acknowledge that they are not an agents of the Clinical Research Team, and have no authority to speak
for, represent or obligate the Clinical Research Team in any way without first receiving written authority to do so from the Clinical
Research Team.

 

		18.	WARRANTY DISCLAIMER AND LIMITATION OF LIABILITY 

 

		A.	NO PARTY MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY TO THE OTHER WITH RESPECT TO THE
NATURE, USEFULNESS OR FUNCTIONING OF ITS BACKGROUND TECHNOLOGY OR THE RESEARCH MATERIALS, OR AS TO WHETHER THE RESEARCH PROGRAM
WILL BE SUCCESSFUL IN ANY RESPECT, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES, INCLUDING ANY WARRANTY
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND PATENT NON-INFRINGEMENT. EACH PARTY ACKNOWLEDGES THAT THE RESEARCH MATERIALS
ARE PROVIDED “AS IS”. EACH PARTY ACKNOWLEDGES THAT THE RESEARCH MATERIALS ARE EXPERIMENTAL IN NATURE AND SHOULD BE
HANDLED WITH CAUTION AND PRUDENCE.

 

		B.	EXCEPT FOR BREACHES OF SECTION 7 NO PARTY SHALL BE LIABLE TO ANOTHER PARTY UNDER OR IN RELATION
TO THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, PUNITIVE, EXEMPLARY, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER, WHETHER
FROM THE PERFORMANCE OR BREACH OF THIS AGREEMENT PROVIDED, HOWEVER, THAT THIS LIMITATION WILL NOT REDUCE OR AFFECT THE PARTIES’
INDEMNIFICATION OBLIGATIONS UNDER SECTION 12 WITH RESPECT TO THIRD PARTY CLAIMS.

 

		19.	MISCELLANEOUS

 

		A.	Force Majeure. Provided that such
failure is cured as soon as is practicable after its occurrence, no party to this Agreement shall be liable for its failure to
perform hereunder due to circumstances beyond its reasonable control, including but not limited to strike, riot, war, fire, act
of God, terrorist act, cyber-attack, pandemic events, accident, lock-outs or power failure, not caused by the fault or neglect
of such party, compliance with any law, regulation or order, whether valid or invalid, of the United States of America or any other
governmental body. The party claiming force majeure will notify the other parties with notice of the force majeure event as soon
as practicable, but in no event later than five (5) business days after its occurrence, which notice will reasonably identify such
obligations under this Agreement and the extent to which performance thereof will be affected. In such event, the parties will
meet promptly to determine an equitable solution to the effects of any such force majeure event, and the party affected by the
force majeure event will use all reasonable efforts to minimize the loss or inconvenience suffered by the other parties.

 

     8

     

    

 

		B.	Entire Agreement. This Agreement
and the exhibits thereto constitute the entire agreement and supersedes all prior agreements and understandings, both written and
oral, between the parties with respect to the Research Program. Nothing contained in this Agreement shall in any way obligate or
require any party to enter into any further agreement or collaboration, regardless of the outcome of the Research Program.

 

		C.	Amendments.
No amendment or modification of this Agreement shall be effective unless such amendment or modification is in writing and signed
by all parties.

  

		D.	Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and the successors to substantially the entire business and assets of the respective parties hereto. This Agreement shall
not be assignable by either party without the prior written consent of the other party; provided, however, that Sponsors may, without
such consent, assign this Agreement and its rights and obligations hereunder to an affiliate or in connection with the transfer
or sale of all or substantially all of its business pertaining to this Agreement, or in the event of any merger or consolidation
or change in control or similar transaction.

 

		E.	Enurement. This Agreement shall enure to the benefit of and be binding upon the parties
hereto and their respective successors and permitted assigns.

 

		F.	Governing Law and Jurisdiction. This Agreement shall be governed by, and construed and enforced
in accordance with the laws of New York State, United States, without regard to any conflict of laws rules to the contrary. The
parties agree that the courts of the state and federal courts of the New York State will have exclusive jurisdiction to determine
all disputes and claims arising between the parties.

 

		G.	Notices. Any notices required to be given or which shall be given under this Agreement shall
be via email or in writing delivered by first class mail (air mail if not domestic) or overnight courier service (e.g., FedEx)
addressed to the parties as follows:

 

Veterinary
Oncology Services, LLC

69 Dakota Drive

Hopewell Junction,
NY 12533

Attn: Dr. Joseph Impellizeri,
DVM, DACVIM (oncology), MRCVS

Phone: (916) 204-1657

E-mail: oncologyvet@yahoo.com

 

Applied
DNA Sciences, Inc.

50 Health Sciences
Drive

Stoney Brook,
NY 11790

Attn: Dr. James
A. Hayward, CEO

Phone: (631)
240-8800

E-mail: james.hayward@adnas.com

 

Evvivax,
S.R.L. 

Via di Castel
Romano 100

00128 Roma,
Italy

Attn: Dr. Luigi
Aurisicchio, CEO

 

E-mail: aurisicchio@evvivax.com

 

In the event notices, statements,
and payments required under this Agreement are sent by certified or registered mail or overnight courier service by one party to
the other party at its above address, they shall be deemed to have been given or made as of the date so mailed, otherwise as of
the date received. Any party may change its notice address and contact person by giving notice of same in the manner provided.

 

		H.	Remedies. The rights and remedies available under this Agreement shall be cumulative and
not alternative and shall be in addition to and not a limitation of any rights and remedies otherwise available to the parties
at law or in equity. No exercise of a specific right or remedy by either party precludes it from or prejudices it in exercising
another right or pursuing another remedy or maintaining an action to which it may otherwise be entitled either at law or in equity.

 

		I.	Severability. If any provision of this Agreement shall be held invalid, illegal or unenforceable,
such provision shall be enforced to the maximum extent permitted by law and the parties' fundamental intentions hereunder, and
the remaining provisions shall not be affected or impaired.

 

[Signature Page Follow]

 

     9

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first written above. 

 

VETERINARY ONCOLOGY SERVICES, LLC

  

	By:	/s/
    Joseph Impellizeri	 
	Name:	Joseph
    Impellizeri	 
	Title:	CMO	 

 

APPLIED DNA SCIENCES, INC. 

 

	By:	/s/ James A. Hayward	 
	Name: 	James Hayward	 
	Title:	 CEO	 

  

EVVIVAX S.R.L. 

 

	By:	/s/ Luigi Aurisicchio	 
	Name:	Dr. Luigi Aurisicchio	 
	Title:	CEO	 

  

     10

     

    

  

EXHIBIT A - RESEARCH
PROGRAM

 

[Intentionally omitted.]

 

     11

     

    

 

Exhibit
B - Financial compensation

 

[Intentionally omitted.]

 

     12

     

    

 

Exhibit
C - Informed Consent 

 

[Intentionally omitted.]

 

     13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]